Zortix matched this thesis to Biotech ETFs as one way for retail investors to get exposure. Not a recommendation.
Biotech discovery favors small, nimble companies
The guest argued that drug discovery is not a scale business, and small, innovative biotech companies often have an advantage over large pharmaceutical firms due to their nimbleness in discovering new science.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.